NCT02722135View on ClinicalTrials.gov

A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

September 30, 2018

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Volasertib

Trial Locations (1)

Unknown

Boehringer Ingelheim Investigational Site, Ghent

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02722135 - A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed | Biotech Hunter | Biotech Hunter